Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513947 | 0.91 | HRH4 (0.41) | HRH4HTR3AHRH3GPER1 | |
| SCHEMBL2559263 | 0.91 | HRH4 (0.42) | HRH4PIK3CAHTR3AHRH3 | |
| SCHEMBL3470840 | 0.91 | HRH4 (0.39) | HRH4HTR3A | |
| SCHEMBL2996570 | 0.90 | HRH4 (0.38) | HRH4HTR3A | |
| SCHEMBL2547197 | 0.90 | HRH4 (0.40) | HRH4HTR3A | |
| SCHEMBL2581265 | 0.89 | HRH4 (0.41) | HRH4HTR3AHRH3 | |
| SCHEMBL2514068 | 0.89 | WDR5 (0.41) | HRH4PIK3CA | |
| SCHEMBL2532614 | 0.89 | HRH4 (0.39) | HRH4HTR3A | |
| SCHEMBL2515304 | 0.89 | PIK3CD (0.42) | HRH4CREBBPPIK3CAHTR3AHRH3 | |
| SCHEMBL2993455 | 0.88 | SCD (0.40) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | claimed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | claimed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | claimed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885CREBBP 3166/4885MAP4K1 1476/4885 |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885CREBBP 3166/4885MAP4K1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.